Wed, Jul 30, 2014, 3:40 PM EDT - U.S. Markets close in 20 mins.

Recent

% | $
Click the to save as a favorite.

Titan Pharmaceuticals Inc. Message Board

  • wallstreetbuyer wallstreetbuyer Aug 25, 2013 11:54 AM Flag

    One important Biotech stock issue; cash

    Not much discussion here. Need two sides of the story. Dilution possible or may be next news before any good news?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • IF Braeburn hangs around, I can see an amended agreement where Braeburn will provide necessary cash to Titan to keep their doors open.IF Braeburn stays,Titan is in a good position.

    • They've got funding until April 2014.

      They normally dilute a month or two before money runs out, so we've got some time.

      Good news (if we get any) will come before dilution.

      • 1 Reply to nowak488
      • Nowak's right on this one. Next (announcement of) dilution would most likely be December or January at earliest, plenty of time for "good news," if any is possible at this point, and that's assuming SB doesn't shoot the company in foot in the meantime (which he's been known to do frequently). Q3 CC in October will be another great "pump" job or it'll probably kill the stock for 2 more years (or longer). Much depends not only "when" they schedule the FDA meeting BUT how it actually goes. If they push the meeting out 4 to 6 months by requesting a "B" or "C" type, dilution is fairly assured. Every December there's a "tax dump" anyway, so the timing is debatable but that timing is far more debatable than the likelihood of more "usury" of shareholder trust. Consistent deceptions and distortions of fact by management will continue. One may choose to trust or not but trading this stock like a game of "hot potato" is probably the best opinion I'd share publicly.

 
TTNP.OB
0.00(0.00%)

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.